Related Experiment Video
Updated: Oct 13, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
M J Piccart1, A Di Leo, A Hamilton
1Institut Jules Bordet, Unite de Chimiotherapie, Rue Héger Bordet 1, B-1000, Brussels, Belgium. mpiccart@ulb.ac.be
Abstract:
The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast tumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family, has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient.
Related Concept Videos
Mitogens and the Cell Cycle
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
